New hope for myeloma patients who relapse after CAR t: bispecific antibody trial launches

NCT ID NCT07009899

Not yet recruiting Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This phase 2 trial tests a drug called linvoseltamab in 34 people with multiple myeloma whose cancer returned after BCMA CAR T-cell therapy. Linvoseltamab is a bispecific antibody that helps the immune system attack myeloma cells. The main goal is to see how many patients respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Linvoseltamab (a bispecific antibody that helps immune cells attack myeloma cells)
What this could lead to: If it works, this could offer a new treatment option for multiple myeloma patients whose cancer has returned after CAR T-cell therapy.
What could go wrong: This is a small, early-phase study (34 people) at one center, so results may not apply broadly. The drug may not work well or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Froedtert & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.